Subtotal $0.00
Feel Free To Contact Us at
- Phone:(888)-896-5577
- Email:dr.koffler@hmwcenter.com
Feel Free To Contact Us at
5-Amino-1MQ is an experimental small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular metabolism and energy regulation. Research in obese mice suggests that NNMT inhibition may reduce fat accumulation and improve insulin sensitivity and other metabolic markers.
However, these findings remain preclinical. There is not yet an established human clinical evidence base demonstrating that 5-Amino-1MQ safely produces meaningful weight loss. That makes 5-Amino-1MQ an interesting fat-loss and metabolic research compound, but not a proven obesity treatment.
Despite often being discussed alongside peptide therapies, 5-Amino-1MQ is not a peptide. It is a synthetic small molecule, also referred to as 5-amino-1-methylquinolinium, that works as an NNMT inhibitor.
This distinguishes it from peptide-based treatments such as semaglutide, tirzepatide, CJC-1295, ipamorelin, and tesamorelin.
The distinction is important because small molecules and peptides can differ significantly in their absorption, distribution, metabolism, elimination, dosing, and safety considerations.
5-Amino-1MQ targets NNMT, or nicotinamide N-methyltransferase.
NNMT uses nicotinamide, a form of vitamin B3, and S-adenosyl-L-methionine (SAM) to produce 1-methylnicotinamide (1-MNA).
Because NNMT intersects with pathways involving:
researchers have investigated whether inhibiting the enzyme could change how fat cells store and use energy.
A simplified model is:
5-Amino-1MQ → NNMT inhibition → altered nicotinamide/SAM metabolism → changes in cellular signaling → reduced lipogenesis and adiposity in experimental models.
The important caveat is that this mechanism has produced promising results primarily in cells and animals. Whether it translates into meaningful human fat loss remains unanswered.
NAD+ is involved in numerous cellular reactions, including energy metabolism and redox balance. SAM is an important methyl-group donor used in processes involving DNA, proteins, neurotransmitters, lipids, and other cellular molecules.
Because NNMT uses nicotinamide and SAM, inhibiting the enzyme can alter the availability of metabolites involved in these pathways.
This is why 5-Amino-1MQ is sometimes marketed as an “NAD+ booster.” That description is too simplistic.
5-Amino-1MQ is not an NAD+ supplement. Its proposed action is to change the metabolic pathway that processes nicotinamide, potentially influencing NAD+- and SAM-related metabolism.
A 2018 study of selective NNMT inhibitors found reductions in body weight and white adipose tissue in diet-induced obese mice.
A 2024 study specifically examining 5A1MQ in obese mice reported:
These findings are scientifically important, but they remain preclinical evidence.
The study did not establish that 5-Amino-1MQ causes weight loss in humans, is safe for long-term human use, treats human insulin resistance or fatty liver disease, or is superior to approved obesity medications.
Animal studies help researchers understand mechanisms, dose responses, tissue effects, metabolism, and potential toxicity.
But human obesity is influenced by many additional factors, including:
A compound can produce impressive changes in obese mice and fail to produce comparable results in humans. That is why human clinical trials are the most important missing piece in the 5-Amino-1MQ research program.
Potentially but this remains a research question. Animal studies have reported improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, liver fat, and liver triglycerides following NNMT inhibition.
These findings suggest that NNMT may be relevant to metabolic dysfunction beyond body weight. However, improved insulin sensitivity or reduced liver fat in mice does not establish 5-Amino-1MQ as a treatment for insulin resistance or MASLD in humans.
There is currently no established human evidence showing that 5-Amino-1MQ suppresses appetite or reliably produces fat loss without affecting food intake.
Some animal studies observed metabolic and adiposity changes without the same appetite-related effects associated with centrally acting weight-loss medications.
That is an interesting research distinction, but it should not become a claim that people can “eat normally and lose fat” with 5-Amino-1MQ.
Some preclinical NNMT research has reported favorable changes in body composition, including improved lean-mass-to-body-weight ratios.
However, human body-composition data are not established. Therefore, claims that 5-Amino-1MQ specifically “burns fat while preserving muscle” remain unproven in humans.
Not in the established clinical sense.
Animal research suggests NNMT inhibition can alter metabolic pathways and energy handling. But there is no established human evidence demonstrating that 5-Amino-1MQ substantially increases calorie expenditure.
Human studies would need to measure outcomes such as:
before meaningful claims about increased metabolism could be made.
No.
There is no established FDA-approved indication for 5-Amino-1MQ as a weight-loss or obesity medication. It should not be presented as an FDA-approved alternative to semaglutide or tirzepatide.
A compound may appear in scientific research, research catalogs, wellness clinics, or compounding environments without being an FDA-approved drug. Availability is not the same as approval or proven efficacy.
Long-term human safety has not been adequately established. There is not yet a sufficiently developed human safety database from which to confidently describe common, rare, or long-term adverse effects.
This means claims such as:
go beyond the available evidence.
Safety research would need to evaluate pharmacokinetics, pharmacodynamics, toxicity, repeated exposure, drug interactions, and long-term effects. Because NNMT participates in normal cellular metabolism, prolonged inhibition could potentially affect pathways beyond adipose tissue. That does not prove harm; it highlights why further research is necessary.
A compounded product is not automatically an FDA-approved medication. Likewise, labels such as “research grade,” “pharmaceutical grade,” or “for research use” do not independently establish that a product is appropriate for human treatment.
Product quality can involve questions about:
This creates a separate issue from the question of whether the molecule itself is safe and effective.
The mechanisms and evidence bases are very different.
| Feature | 5-Amino-1MQ | Semaglutide / Tirzepatide |
|---|---|---|
| Category | Small molecule | Peptide-based medications |
| Primary pathway | NNMT | GLP-1 / GIP |
| Human obesity evidence | Not established | Extensive |
| FDA-approved obesity indications | No | Yes, for eligible patients |
| Human dosing evidence | Not established | Established |
| Current evidence | Primarily preclinical | Substantial clinical evidence |
For obesity treatment, these are not equivalent evidence categories.
Semaglutide and tirzepatide have substantially stronger human clinical evidence. The reason researchers remain interested in 5-Amino-1MQ is that it represents a different potential metabolic strategy, not because it has already demonstrated superiority.
This is a potential area for future research because the mechanisms are different:
GLP-1/GIP therapies → appetite and metabolic signaling
NNMT inhibition → cellular and adipose metabolic pathways
However, different mechanisms do not automatically mean that combining treatments is safe or synergistic.
Clinical studies would need to demonstrate additive benefit, acceptable safety, compatible pharmacokinetics, and meaningful patient outcomes before such combinations could be considered established therapy.
The next major step is human clinical research.
Researchers would need to establish:
Phase 1: Safety, tolerability, pharmacokinetics and dosing.
Phase 2: Effects on weight, fat mass, glucose, insulin sensitivity and metabolic markers.
Phase 3: Durability of weight loss, long-term safety, effects on obesity-related conditions and comparisons with established treatments.
Long-term follow-up would also be necessary to understand whether benefits persist and whether delayed adverse effects emerge.
| Claim | What the evidence supports |
|---|---|
| “5-Amino-1MQ burns fat.” | Fat-mass reductions have been observed in animals; human efficacy is unproven. |
| “It increases metabolism.” | Metabolic effects are seen experimentally; meaningful human effects are unknown. |
| “It boosts NAD+.” | NNMT inhibition can alter NAD+-related metabolism in experimental models. |
| “It causes weight loss without dieting.” | Not established in humans. |
| “It preserves muscle.” | Some animal findings are encouraging; human evidence is lacking. |
| “It treats insulin resistance.” | Improved insulin sensitivity has been reported in mice; human efficacy is unproven. |
| “It treats fatty liver.” | Improvements have been reported in mice; human efficacy is unproven. |
| “It is a peptide.” | No. It is a small-molecule NNMT inhibitor. |
| “It is FDA approved.” | No FDA-approved weight-loss indication has been established. |
| “It is proven safe.” | Human safety data remain insufficient. |
5-Amino-1MQ is an intriguing research compound because it targets NNMT, a metabolic pathway connected with nicotinamide, NAD+, SAM, lipid metabolism and adipose-tissue function.
Preclinical research has produced encouraging findings involving fat mass, glucose metabolism, insulin sensitivity and liver fat.
At present, there is not enough clinical evidence to say that it does. For someone considering treatment for obesity, insulin resistance, fatty liver, or difficulty losing weight, the better starting point is the specific health problem and the treatments with the strongest evidence, rather than choosing an experimental compound based on its mechanism alone.
5-Amino-1MQ shows promise for blood sugar support, but those with metabolic or hormonal issues should consult a doctor before use.
5-Amino1MQ is an experimental small-molecule inhibitor of NNMT, an enzyme involved in nicotinamide and SAM metabolism. It is being studied for potential effects on obesity and metabolic health.
No. Despite being marketed alongside peptide therapies, 5-Amino-1MQ is a small-molecule NNMT inhibitor.
It has reduced fat mass and body-weight gain in obese mouse models. Whether it produces meaningful fat loss in humans has not been established.
There is no established human clinical efficacy dataset demonstrating that it produces weight loss. The available evidence remains predominantly preclinical.
No. There is no established FDA-approved weight-loss indication for 5-Amino-1MQ.
Its long-term human safety profile remains insufficiently characterized. Animal studies cannot establish long-term safety in people.
NNMT inhibition can alter NAD+-related metabolism in experimental models. This does not establish that 5-Amino-1MQ increases NAD+ or improves longevity in humans.
Animal studies have reported improvements in insulin sensitivity and liver-related measures. These effects have not been established as treatments for insulin resistance or fatty liver disease in humans.
There is no evidence supporting that conclusion. Semaglutide and tirzepatide have a substantially stronger human clinical evidence base for obesity treatment.
There is no adequately validated human dose established through clinical trials. Animal dosing should not be converted into a self-treatment regimen.
